Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: forgetme	3/29/2025 12:37:35 PM
	of 63304

atnm stocktitan.net "What's technically innovative here is ATNM-400's dual differentiation from market leader Pluvicto: it targets a non-PSMA marker and utilizes Actinium-225, an alpha-particle emitter with higher potency and shorter path length than Lutetium-177. This approach could potentially address two critical limitations in current radiotherapeutics: resistance mechanisms and off-target toxicity." Current approved radioligand sales figure:Pluvicto Novartis' Pluvicto, a radioligand therapy for prostate cancer, achieved $1.39 billion in sales in 2024, a 42% increase from the previous year, solidifying its position as the first blockbuster drug in the nuclear medicine field.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next